(Prostate Cancer) Is PARP Inhibitor Rucaparib Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
On August 14, 2020, Wassim Abida published results in the Journal of Clinical Oncology from the TRITON2 Phase 2 clinical trial evaluating the efficacy and safety of the PARP inhibitor Rucaparib in patients with BRCA1/BRCA2 gene mutation-positive, metastatic castration-resistant prostate cancer.
The TRITON2 Phase 2 trial enrolled 115 previously treated patients with BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer, who received Rucaparib monotherapy twice daily. The primary endpoints were objective response rate (ORR) and PSA response rate.
Approximately 12% of metastatic castration-resistant prostate cancer patients carry BRCA1 or BRCA2 gene mutations. These mutations increase the risk of prostate cancer development and metastasis. Because PARP inhibitors can suppress homologous recombination repair defects and DNA damage responses caused by BRCA1/BRCA2 mutations, they were expected to benefit this patient population.
Results:
- Primary endpoint ORR (IRC-assessed): 43.5%
- Primary endpoint ORR (investigator-assessed): 50.8%
- PSA response rate: 54.8%
Conclusion: Based on the TRITON2 trial results, Wassim Abida concluded that Rucaparib demonstrated meaningful anti-tumor activity in BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer patients, with a safety profile consistent with previously known adverse event data from other clinical trials.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Translation materials are for reference only. Please consult your healthcare provider for medical decisions.
Source: Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Aug 14; JCO2001035. doi: 10.1200/JCO.20.01035.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4